Harmony Biosciences Holdings, Inc. (HRMY) financial statements (2022 and earlier)

Company profile

Business Address 630 W GERMANTOWN PIKE
PLYMOUTH MEETING, PA 19462
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments234,309228,631
Cash and cash equivalents234,309228,631
Receivables34,84322,176
Inventory, net of allowances, customer advances and progress billings4,4323,823
Inventory4,4323,823
Prepaid expense7,6376,959
Other current assets3,2181,302
Total current assets:284,439262,891
Noncurrent Assets
Property, plant and equipment820938
Intangible assets, net (including goodwill)143,919162,343
Intangible assets, net (excluding goodwill)143,919162,343
Restricted cash and investments750750
Other noncurrent assets3,515152
Total noncurrent assets:149,004164,183
TOTAL ASSETS:433,443427,074
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities50,415134,225
Accounts payable1,0012,556
Accrued liabilities40,249122,727
Employee-related liabilities9,1658,942
Debt2,000 
Other liabilities1,360314
Total current liabilities:53,775134,539
Noncurrent Liabilities
Long-term debt and lease obligation189,984194,250
Long-term debt, excluding current maturities189,984194,250
Liabilities, other than long-term debt3,1771,105
Deferred rent credit 212
Other liabilities3,177893
Total noncurrent liabilities:193,161195,355
Total liabilities:246,936329,894
Stockholders' equity
Stockholders' equity attributable to parent186,50797,180
Common stock11
Additional paid in capital640,104585,374
Accumulated deficit(453,598)(488,195)
Total stockholders' equity:186,50797,180
TOTAL LIABILITIES AND EQUITY:433,443427,074

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
Revenues305,440159,742
Cost of revenue
(Cost of Goods and Services Sold)
(55,518)(27,738)
Gross profit:249,922132,004
Operating expenses(162,394)(115,018)
Operating income:87,52816,986
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
16(3,071)
Interest and debt expense(26,146)(22,639)
Income (loss) from continuing operations before equity method investments, income taxes:61,398(8,724)
Other undisclosed loss from continuing operations before income taxes(23,970)(28,220)
Income (loss) from continuing operations before income taxes:37,428(36,944)
Income tax expense (benefit)(2,831)4,436
Income (loss) before gain (loss) on sale of properties:34,597(32,508)
Other undisclosed net loss (4,436)
Net income (loss) attributable to parent:34,597(36,944)
Preferred stock dividends and other adjustments (26,904)
Net income (loss) available to common stockholders, diluted:34,597(63,848)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
Net income (loss):34,597(36,944)
Comprehensive income (loss), net of tax, attributable to parent:34,597(36,944)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: